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Background: Autosomal recessive limb-girdle muscular dystrophies (LGMD2) include a number of disorders with
heterogeneous etiology that cause predominantly weakness and wasting of the shoulder and pelvic girdle muscles.
In this study, we determined the frequency of LGMD subtypes within a cohort of Czech LGMD2 patients using
mutational analysis of the CAPN3, FKRP, SGCA, and ANO5 genes.
Methods: PCR-sequencing analysis; sequence capture and targeted resequencing.
Results: Mutations of the CAPN3 gene are the most common cause of LGMD2, and mutations in this gene were
identified in 71 patients in a set of 218 Czech probands with a suspicion of LGMD2. Totally, we detected 37
different mutations of which 12 have been described only in Czech LGMD2A patients. The mutation c.550delA
is the most frequent among our LGMD2A probands and was detected in 47.1% of CAPN3 mutant alleles. The
frequency of particular forms of LGMD2 was 32.6% for LGMD2A (71 probands), 4.1% for LGMD2I (9 probands),
2.8% for LGMD2D (6 probands), and 1.4% for LGMD2L (3 probands).
Further, we present the first results of a new approach established in the Czech Republic for diagnosis of
neuromuscular diseases: sequence capture and targeted resequencing. Using this approach, we identified patients
with mutations in the DYSF and SGCB genes.
Conclusions: We characterised a cohort of Czech LGMD2 patients on the basis of mutation analysis of genes
associated with the most common forms of LGMD2 in the European population and subsequently compared the
occurrence of particular forms of LGMD2 among countries on the basis of our results and published studies.
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Limb-girdle muscular dystrophies (LGMD) are charac-
terised by wide clinical and genetic heterogeneity. Con-
sidering this factor, achieving a precise diagnosis can be
difficult and requires a comprehensive clinical and la-
boratory approach. LGMD are classified on the basis of
an inheritance pattern and a genetic cause. Limb-girdle
muscular dystrophies of type 1 (LGMD1) include forms
of the disorder that have an autosomal dominant inherit-
ance associated with a mutation in one of at least 8* Correspondence: lenka.fajkus@gmail.com
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unless otherwise stated.genes (LGMD1A-1H). Limb-girdle muscular dystrophies
of type 2 (LGMD2) include forms with an autosomal re-
cessive inheritance and mutations in one of at least 16
genes (LGMD2A-Q).
It is helpful to take into account the geographical and
ethnic origins of patients in differential diagnosis, since
the relative local frequency of the different forms of
LGMD varies considerably [1-4]. The clinical course of
LGMD ranges from severe to milder forms with different
age of onset and progression even within the same family
[5]. Diagnosis of LGMD relies on a combination of clinical
findings, results of histopathological examination of muscle
biopsies (including the analysis of muscle proteins using
immunohistochemistry and/or immunoblotting), followed
by DNA sequencing to identify the primary mutation,tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tic counselling.
The most frequent form of LGMD2 in Europe is prob-
ably LGMD2A, caused by mutations in the calpain-3
gene (CAPN3). This gene encodes a muscle-specific
member of the family of Ca2+-activated neutral proteases
that is important for muscle remodelling [6-8]. A marked
clinical heterogeneity is observed in calpainopathies.
While null-type gene mutations are usually associated
with absence of calpain-3 protein in muscle and a severe
phenotype, missense-type mutations are associated with
unpredictable effects at both the protein and the pheno-
type levels [9-11].
Mutations in the fukutin-related protein gene (FKRP)
result in two distinct allelic diseases: severe congenital
muscular dystrophy and LGMD2I [12]. This gene en-
codes a putative Golgi-resident glycosyltransferase that is in-
volved in posttranslational glycosylation of α-dystroglycan.
The missense mutation c.826C >A, p.Leu276Ile is particu-
larly common in LGMD2I patients and has been reported
to confer a relatively mild phenotype when present in the
homozygous state [13-15].
LGMD2C-2F is due to mutations in the genes encod-
ing the components of the sarcoglycan (SG) complex.
This complex, composed of 5 glycoproteins (α-, β-, γ-, δ-,
ε-SG), is a member of the dystrophin-associated glycopro-
tein (DAG) complex localised to the sarcolemma of
muscle fibres, which acts as a link between the extracellu-
lar matrix and the cytoskeleton, confers structural stabil-
ity, and protects the sarcolemma from mechanical stress
developed during muscle contraction. The clinical pheno-
type of sarcoglycanopathies ranges from a severe
Duchenne-like dystrophy to a relatively mild LGMD [16].
Although the relative frequency of mutations in the differ-
ent sarcoglycan genes varies from population to popula-
tion, α-sarcoglycanopathy (LGMD2D) appears to be the
most frequent [17].
Recently, recessive mutations in the anoctamin 5 gene
(ANO5) were identified as a cause of LGMD2L and non-
dysferlin Miyoshi myopathy [18,19]. ANO5 encodes a
member of the anoctamin family of proteins which con-
tains eight transmembrane domains. Dominant mutations
in the ANO5 gene are associated with the skeletal disorder
gnathodiaphyseal dysplasia [20]. While the role of ANO5
is unknown, ANO1 and ANO2, which share significant se-
quence homology with ANO5, are known to be calcium-
activated chloride channels [21-23]. In one study [24], ana-
lysis of ANO5 was performed in a group of 59 British and
German probands, and the mutation c.191dupA was found
in 15 patients, homozygously in 11 and in compound het-
erozygosity with another ANO5 variant in the rest. An in-
tragenic SNP and an extragenic microsatellite marker were
in linkage disequilibrium with the mutation, suggesting a
founder effect in the populations analysed.In this study, we determined the frequency of LGMD
subtypes within a cohort of Czech LGMD2 patients
using mutation analysis of the CAPN3, FKRP, SGCA, and
ANO5 genes. We also describe two patients with mutations
in the gene encoding dysferlin (DYSF) and a patient with
mutations in the gene encoding β-sarcoglycan (SGCB).
These mutations were identified using Sequence capture
and targeted resequencing (SeqCap-TR), a method for the
capture and enrichment of selected genomic regions from
full genomic DNA in a single step which, in association
with targeted resequencing, allows one to focus on gen-
omic regions of interest to discover causative mutations.
Methods
Patients
For analysis of genes associated with LGMD2, patients’
blood or DNA were sent to the Centre of Molecular
Biology and Gene Therapy, University Hospital Brno (as
the only laboratory performing LGMD genetic testing in
the Czech Republic) from the Departments of Neurology
and Medical Genetics of University Hospitals located in
Brno, Prague, Ostrava, and Hradec Králové. Patients were
included into the study on the basis of fulfilment of the
following criteria: 1) a clinical phenotype characterized
by progressive muscle weakness affecting primarily or
predominantly the pelvic and/or shoulder girdle muscles
and 2) dystrophic or myopathic features at muscle biopsy
(if performed). Pathological analyses of muscle tissues
were performed at the Institute of Pathology, University
Hospital Brno, Brno and the Department of Pathology and
Molecular Medicine, University Hospital Motol, Prague.
Detailed clinical information was requested retrospectively
on the basis of positive results of DNA analysis. Patients
diagnosed with Duchenne muscular dystrophy, spinal
muscular atrophy type III, or facioscapulohumeral muscu-
lar dystrophy were excluded using DNA analysis, and
those with late-onset Pompe disease using the enzyme
assay. DNA analysis reported in this study was performed
with the approval of the Ethical Committee of the Univer-
sity Hospital Brno, and all patients or their parents gave
their informed consent for participation in the study.
Analysis of muscle tissue
Muscle tissues were routinely examined by conventional
histopathological methods. Muscle protein analyses were
performed using immunohistochemistry and immuno-
blotting as described in our previous studies [25-27].
DNA analysis
Genomic DNA was extracted from peripheral blood leu-
kocytes by the standard salting-out method and amplified.
Sequences of primers for amplification of all exons and
adjacent intron sequences are available on request, as well
as the conditions of particular PCRs. PCR products were
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Sequencing Kit (Applied Biosystems) and analysed on the
ABI PRISM 310 or ABI 3130xl Genetic Analyzer (Applied
Biosystems). The resulting sequences were compared
with the reference sequences of CAPN3 (NCBI NG_
008660.1), FKRP (NCBI NG_008898.1), SGCA (NCBI
NG_008889.1), ANO5 (NCBI NG_015844.1), DYSF (NCBI
NG_008694.1), and SGCB (NCBI NG_008891.1). To find
out whether the sequence variations detected had been
described previously, we used the literature and the
Leiden Muscular Dystrophy Pages (LMDP, http://www.
dmd.nl/nmdb/home.php?action=switch_db). All novel mis-
sense mutations were screened in a control panel consist-
ing of DNA from 150 healthy Czech individuals. The in
silico approaches PolyPhen (http://genetics.bwh.harvard.
edu/pph2/index.shtml), SIFT (http://sift.jcvi.org/www/
SIFT_BLink_submit.html), and PON-P (http://structure.
bmc.lu.se/PON-P2/), were used for predicting effects of
novel missense mutations on the function and the structure
of proteins. For prediction of effects of mutations on
splicing of pre-mRNA, the in silico tools NetGene2 (http://
www.cbs.dtu.dk/services/NetGene2/) and SpliceView (http://
bioinfo4.itb.cnr.it/~webgene/wwwspliceview_ex.html) were
used. The nomenclature of mutations was implemented
according to the current HGVS recommendations (http://
www.hgvs.org/mutnomen/). In patients with one mutation
in the CAPN3 gene, detection of deletions/duplications was
performed using multiplex ligation-dependent probe ampli-
fication (MLPA). We used the SALSA MLPA P176 CAPN3
probemix kit (MRC Holland) according to the manufac-
turer’s guidelines. Some CAPN3 mutations were also de-
scribed at the mRNA level in our previous studies [25-27].
We started DNA analysis of LGMD2 patients in 2002
when sequencing analysis of the CAPN3 gene was intro-
duced, and results for other genes were integrated subse-
quently. Patients were analysed step by step for mutations
in the CAPN3, FKRP, SGCA, and ANO5 genes. In CAPN3
and SGCA, all exons and adjacent intron regions were se-
quenced. In FKRP and ANO5, we analysed only exons
with the occurrence of the most common mutations p.
Leu276Ile and c.191dupA, respectively. In case of patients
heterozygous for these mutations, analysis of all exons
of a relevant gene was performed. The mentioned genes
were selected on the basis of published results related
to a higher incidence of associated types of LGMD2 in
European populations [28-30]. The CAPN3 gene was ana-
lysed in 218 Czech LGMD2 probands; the most common
mutation p.Leu276Ile in the FKRP gene in 151 probands
(negative for CAPN3 mutations); the SGCA gene in 142
probands (negative for CAPN3 and FKRP mutations);
and the most common mutation c.191dupA in the ANO5
gene in 136 probands (negative for CAPN3, FKRP, and
SGCA mutations). Two patients carried the mutation
p.Leu276Ile on only one FKRP allele and similarly 3patients carried the mutation c.191dupA on only one
ANO5 allele. As mentioned above, analysis of all exons of
the corresponding gene was performed in these cases.
Sequence capture and targeted resequencing (SeqCap-RT)
For identification of mutations associated with neuro-
muscular disorders, we introduced the solution-based
capture method SeqCap EZ Choice Library (Roche Nim-
bleGene) and targeted resequencing on the GS Junior
System (Roche) in 2013. A custom capture array was de-
signed to capture exons and adjacent intron sequences
of 42 genes (1020 exons, 280 kb) known to be associated
with muscular dystrophies (Group 1), congenital muscular
dystrophies (Group 2), congenital myopathies (Group 3),
distal myopathies (Group 4), and other myopathies
(Group 5), according to www.musclegenetable.fr/. The list
of selected diseases and genes includes Duchenne muscu-
lar dystrophy (DMD), Emery-Dreifuss muscular dystrophy
(EMD, FHL1, LMNA), limb-girdle muscular dystrophy
(MYOT, LMNA, CAV3, CAPN3, DYSF, SGCG, SGCA,
SGCB, SGCD, TCAP, TRIM32, FKRP, TTN, POMT1,
ANO5, FKTN, POMT2, POMGNT1), and additionally
genes associated with congenital muscular dystrophies
(LAMA2, LARGE, SEPN1, COL6A1, COL6A2,
COL6A3, ITGA7, DNM2), congenital myopathies, distal
myopathies, and other myopathies (NEB, TPM3, ACTA1,
TPM2, TNNT1, CFL2, RYR, MTM1, BIN, CRYAB,
DES, LAMP2, PABPN1). Probes for the target regions
were designed according to the “NimbleGen Sequence
Capture Custom Designs” protocol. Sequence capture
was performed according to the manufacturer’s instruc-
tions (NimbleGen SeqCap EZ Choice Library LR User’s
Guide) with modifications of DNA fragmentation and
hybridisation. We replaced nebulization by shearing
using the S220 Focused Ultrasonicator (Covaris) (3 μg
DNA, peak incident power 140 W, duty factor 10%,
200 cycles per burst, and treatment time 80 s) and re-
placed hybridization for three days by hybridization
according to the NimbleGen technical note “Double Cap-
ture High Efficiency Sequence Capture of Small Targets
for use in SeqCap EZ Library, Applications on 454 Se-
quencing Systems”. Emulsion PCR and sequencing on the
GS Junior System (Roche) were performed according to
the “emPCR Amplification Method Manual - Lib-L” and
the “Sequencing Method Manual”. Sequencing data were
evaluated using the software Sequence Pilot (JSI Medical
Systems).
In the period of this study SeqCap-TR was performed in
20 probands of whom 4 had the phenotype of LGMD2 and
were negative for CAPN3, FKRP, SGCA, and ANO5 muta-
tions. Here we present only results for patients in which
mutations in genes associated with LGMD2 were identified,
and the global results and results related to other genes are
the subject of another study to be published.
Table 1 Mutations identified in Czech LGMD2A probands
No. Mutations (cDNA level) Mutations (protein level)
1 - 23 c.550delA/c.550delA p.(Thr184Argfs*36)/p.(Thr184Argfs*36)
24, 25 c.550delA/c.245C > T p.(Thr184Argfs*36)/p.(Pro82Leu)
26 c.550delA/c.328C > T p.(Thr184Argfs*36)/p.(Arg110*)
27 c.550delA/c.509A > G p.(Thr184Argfs*36)/p.(Tyr170Cys)
28 c.550delA/c.598_612del p.Thr184Argfs*36/p.Phe200_Leu204del
29 c.550delA/c.1043delG p.(Thr184Argfs*36)/p.(Gly348Valfs*4)
30 c.550delA/c.1069C > T p.(Thr184Argfs*36)/p.(Arg357Trp)
31 c.550delA/c.1451T > C p.(Thr184Argfs*36)/p.(Leu484Pro)
32 c.550delA/c.1465C > T p.(Thr184Argfs*36)/p.(Arg489Trp)
33, 34 c.550delA/c.1468C > T p.Thr184Argfs*36/p.(Arg490Trp)
35 c.550delA/c.1470delG p.(Thr184Argfs*36)/p.(Arg490Argfs*6)
36, 37 c.550delA/c.1722delC p.Thr184Argfs*36/p.Ser575Leufs*20
38 c.550delA/c.1823G > A p.(Thr184Argfs*36)/p.(Arg608Lys)
39 c.550delA/c.1981delA p.Thr184Argfs*36/p.Ile661*
40 c.550delA/c.2245A > C p.(Thr184Argfs*36)/p.(Asn749His)
41 c.1A > G/c.865C > T p.(Met1Val)/p.(Arg289Trp)
42 c.133G > A/c.133G > A p.Ala45Thr/p.Ala45Thr
43 c.146G > A/c.1069C > T p.(Arg49His)/p.(Arg357Trp)
44 c.224A > G/c.224A > G p.Tyr75Cys/p.Tyr75Cys
45 c.245C > T/c.245C > T p.Pro82Leu/p.Pro82Leu
46 c.245C > T/c.1800 + 1G > A p.(Pro82Leu)/splicing
47 c.245C > T/c.1855C > T p.(Pro82Leu)/p.(Gln619*)
48 c.245C > T/c.2314_2317del p.Pro82Leu/p.Asp772Asnfs*3
49 c.509A > G/c.509A > G p.(Tyr170Cys)/p.(Tyr170Cys)
50 c.598_612del/c.598_612del p.(Phe200_Leu204del)/p.(Phe200_Leu204del)
51 c.598_612del/c.640G > A p.(Phe200_Leu204del)/p.(Gly214Ser)
52 c.598_612del/c.2245A > C p.Phe200_Leu204del/p.Asn749His
53 c.1043delG/c.1094G > A p.(Gly348Valfs*4)/p.(Trp365*)
54 c.1043delG/c.1343G > A p.(Gly348Valfs*4)/p.(Arg448His)
55 c.1194-9A > G/c.1800 + 1G > A splicing/splicing
56 c.1194-9A > G/c.2393C > A splicing/p.(Ala798Glu)
57 c.1250C > T/c.1250C > T p.(Thr417Met)/p.(Thr417Met)
58 c.1322G > A/c.1322G > A p.Gly441Asn/p.Gly441Asn
59 c.1322delG/c.2114A > G p.(Gly441Valfs*22)/p.(Asp705Gly)
60 c.1343G > A/c.2093G > A p.(Arg448His)/p.(Arg698His)
61 c.1468C > T/c.2314_2317del p.(Arg490Trp)/p.(Asp772Asnfs*3)
62 c.1788_1793del/c.2242C > T p.Lys597_Lys598del/p.Arg748*
63 - 66 c.598_612del/c.1746-20C > G p.(Phe200_Leu204del)/splicing
67 c.614T > C/c.1746-20C > G p.(Leu205Pro)/splicing
68, 69 c.550delA/- p.(Thr184Argfs*36)/-
70, 71 c.598_612del/- p.(Phe200_Leu204del)/-
Mutations in bold letters were detected only in Czech LGMD2A patients.
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Considering the wide clinical and genetic variability of
LGMD, determination of particular types is a compre-
hensive process. Muscle biopsies still represent an im-
portant and economical step in diagnosis, but protein
changes documented by immunohistochemistry can be
secondary or not pronounced and therefore a definitive
diagnosis requires genetic analysis. Mutations of the
CAPN3 gene are the most common cause of LGMD2,
and in the set of 218 Czech probands with a suspicion
of LGMD2 two mutations in this gene were identified in
67 patients. In 4 patients only one CAPN3 mutation was
determined, and sequence analysis was completed by
MLPA but no gene deletions/duplications were found
(Table 1). In total we identified 37 different mutations of
which 12 have been described only in Czech LGMD2A
patients. The most frequent mutation among our
LGMD2A probands is c.550delA which was detected in
65 mutant alleles from the total number of 138 (47.1%).
The patients’ clinical and pathological findings (when
available) are presented in (Additional file 1: Table S1).
Probands negative for CAPN3 mutations (151) were ana-
lysed for the most common mutation in the FKRP gene,
p.Leu276Ile. The homozygous occurrence of this muta-
tion was identified in 7 patients. In two patients heterozy-
gous for p.(Leu276Ile), we were able to identify a second
mutation: patient 79 carries the mutation p.(Pro316Arg)
described in [12] and patient 80 has the new mutation
p.(Trp359Ser) (Table 2).
In 142 probands without mutations in the CAPN3 or
FKRP genes, we performed analysis of the SGCA gene.
Mutations were detected in 6 patients (Table 2). The
most common mutation among our LGMD2D patients
is p.(Arg77Cys), which was present in 4 mutant alleles.Table 2 Mutations identified in Czech LGMD2I, 2D, 2 L, 2B, an
No. Gene Mutation (cDNA level)
72 - 78 FKRP c.826C > A/c.826C > A
79 FKRP c.826C > A/c.947C > G
80 FKRP c.826C > A/c.1076G > C
81 SGCA c.229C > T/c.229C > T
82, 83 SGCA c.157 + 1G > A/c.850C > T
84 SGCA c.229C > T/c.739G > A
85 SGCA c.290A > G/c.303dupA
86 SGCA c.229C > T/c.308 T > C
87 ANO5 c.191dupA/c.966A > T
88, 89 ANO5 c.191dupA/c.2272C > T
90 DYSF c.3832C > T/c.5509G > T
91 DYSF c.509C > A/c.5907G > C/c.610C > T/c.1120G
92 SGCB c.341C > T/c.341C > T
Mutations in bold letters were detected only in Czech LGMD2 patients. The variant
(LMDP, dbSNP-rs7481951).We also identified one new SGCA mutation, c.303dupA
(patient 85).
Probands negative for CAPN3, FKRP, and SGCA muta-
tions (136) were screened for the most common muta-
tion in the ANO5 gene, c.191dupA. This mutation was
found heterozygously in 3 patients, and subsequent se-
quencing analysis of all exons and adjacent intron re-
gions detected the mutation p.(Arg758Lys) in two of
them (Table 2). This mutation was described in combin-
ation with c.191dupA in other studies [24], [31] and the
associated phenotypes corresponded to distal non-
dysferlin Miyoshi myopathy, unlike our patient 88 whose
phenotype matches rather LGMD2L (a detailed descrip-
tion of the phenotype of patient 89 was not available).
Analysis for this mutation was subsequently performed
in all LGMD2 patients with unconfirmed diagnosis at the
DNA level, but it was not detected. In patient 87 carrying
c.191dupA on one allele, we did not identify a second mu-
tation but only the polymorphism p.(Leu322Phe) de-
scribed in LMDP. The patient’s clinical and pathological
findings are presented in (Additional file 2: Table S2).
The aim of this study was to evaluate the relative pro-
portion of the most frequent types of LGMD2 identified
in other European countries in Czech probands with a
suspicion of LGMD2. The results show that the fre-
quency of the forms of LGMD2 which were analysed is
32.6% for LGMD2A (71 probands), 4.1% for LGMD2I
(9 probands), 2.8% for LGMD2D (6 probands), and
1.4% for LGMD2L (3 probands). These results indi-
cate that there is good agreement between the fre-
quency of particular forms of LGMD2 in the Czech
Republic and in Italy (respectively LGMD2A 31.1%,
LGMD2I 7.4%, LGMD2D 8.4%, LGMD2L 2.1% [28]















c.966A > T in italics is probably a nucleotide polymorphism
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frequency of LGMD2A is significantly lower (12.1%)
and that of LGMD2I significantly higher (38.4%) [29]
(Table 3).
Histopathological and immunohistochemical analysis
of muscle tissue performed in 42 of the 71 patients with
identified mutation(s) in the CAPN3 gene showed that
34 patients had a dystrophic and 8 had a myopathic pat-
tern of muscle tissue. Immunoblotting of the CAPN3
protein was implemented in 33 patients. In patients with
a mutation creating a protein termination codon (PTC)
on both CAPN3 alleles, immunoblotting showed the ab-
sence of 94 kDa CAPN3 (16 cases); in patients with a
combination PTC/missense mutation we noted the ab-
sence (4 patients) or weak labelling (2 patients) of CAPN3;
and in cases with a combination missense/missense muta-
tion we detected the absence (2 patients), weak labelling
(1 patient), or normal labelling (1 patient) of CAPN3.
Other cases encompassing combinations of in-frame dele-
tions, splicing mutations, or with a mutation on one
CAPN3 allele occurred exceptionally (Additional file 1).
Analysis of muscle tissue performed in 6 patients with
mutations in the FKRP gene showed a dystrophic pat-
tern of muscle tissue. In two cases (patients 72 and 78),
immunohistochemical analysis of alpha-dystroglycan
was performed and both patients had a deficit of this
protein. Three patients with mutations in the SGCA gene
showed absence or weak labelling of alpha, beta, and
gamma-sarcoglycans (patients 82, 85), but in contrastTable 3 Frequency of LGMD2A, 2I, 2D, 2 L in European count
Litera-
ture






Czech 218 LGMD2 probands 71 (67 had two
4 one); 32.6%
[28] Italy 190 LGMD probands 59; 31.1%
[2] Italy 155 LGMD probands 44 (30 had two
14 one); 28.4%
[32] Italy 550 patients with LGMD, myopathy,
or asymptomatic hyperCKemia
102; 18.5%
[33] Italy 519 patients with LGMD, myopathy,
or asymptomatic hyperCKemia
94 (76 had two
18 one); 18.1%
[10] Italy 530 patients with muscular dytrophy 141 (104 had tw
and 37 one); 26
[34] Italy 214 probands with muscular
dystrophy or myopathy
NI
[35] Germany 98 probands with LGMD2 and 102
probands with asymptomatic or
minimally symptomatic hyperCKemia
NI
[29] Denmark 99 LGMD2 patients 12; 12.1%
[4] Dutch 67 LGMD probands 14; 20.9%
[30] Dutch 68 LGMD probands NI
NI: no information.immunodetection of these proteins was normal in patient
84 (Additional file 2).
In 2013, we introduced the SeqCap-TR method for
genetic diagnosis of neuromuscular disorders and this
approach was applied in 20 patients, 4 of whom had the
LGMD2 phenotype and were negative for CAPN3, FKRP,
SGCA, and ANO5 mutations. We identified two patients
with LGMD2B (mutations in the DYSF gene), one pa-
tient with LGMD2E (mutations in the SGCB gene), and
one patient is without identified causal mutations as yet.
Patient 90 is a compound heterozygote for two DYSF
mutations (genotype p.[Gln1278*]; [Asp1837Tyr]). Com-
pound heterozygous and homozygous occurrence of p.
(Gln1278*) was described in [36], in the case of a homozy-
gous patient an initial phenotype corresponded to Miyoshi
myopathy. The mutation c.5509G > T, p.(Asp1837Tyr)
was not reported so far, but c.5509G >A, p.(Asp1837Asn)
was described in several studies. In [37] a patient carried
the genotype p.[Asp1837Asn]; [Trp1968*] and the pheno-
type of LGMD2B, and in [38] and [39] patients with the
genotype p.[Asp1837Asn]; [Tyr522*] had Miyoshi my-
opathy. In cases of homozygous occurrence of this muta-
tion, phenotypes of Miyoshi myopathy [40-42] and also
of LGMD2B [42] were observed. The phenotype of
our patient 90 corresponded rather with LGMD2B.
Patient 91 carries 4 mutations in the DYSF gene, p.
(Ala170Glu), p.(Arg204*), p.(Val374Leu), and the novel
mutation p.(Trp1969Cys). The mutation p.(Ala170Glu) is













mutations, 9; 4.1% 6; 2.8% 3; 1.4%
14; 7.4% 16; 8.4% 4; 2.1%
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13 (9 had two mutations,
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not pathogenic or pathogenic. The evaluation of these
missense mutations using in silico tools is described in
(Additional file 3: Table S3) together with the evaluation
of selected missense mutations identified in the genes ana-
lysed. DNA analysis was performed in patient’s parents;
her father carries p.(Arg204*) and p.(Val374Leu), and her
mother carries p.(Ala170Glu) and p.(Trp1969Cys). On the
basis of the in silico analyses and inheritance in the patient’s
family, we suppose that p.(Arg204*) and p.(Trp1969Cys)
are causal mutations. Patient 92 is homozygous for the
SGCB mutation p.(Ser114Phe) described in the LMDP in
association with LGMD2E. The patients’ clinical and patho-
logical findings are shown in (Additional file 2: Table S2).
None of the novel missense mutations were detected in
150 control DNA samples.
Conclusions
We characterised a cohort of Czech LGMD2 patients on
the basis of analysis of mutations in genes associated
with the most common forms of LGMD2 in the European
population and compared these results with published
studies. This study expands our previous results for the
Czech LGMD2A population [25-27], as well as the
spectrum of mutations in other types of LGMD2, and fur-
ther provides information concerning clinical and genetic
correlations. At the present time, molecular genetic diag-
nosis of Czech LGMD2 patients follows the following
scheme: sequencing of all exons and adjacent intron re-
gions of the CAPN3 gene, detection of the most common
mutation p.Leu276Ile in the FKRP gene, and sequence
capture and targeted resequencing of genes associated
with neuromuscular disorders.
Additional files
Additional file 1: Table S1. Mutations and pathological-clinical findings
identified in Czech LGMD2A probands.
Additional file 2: Table S2. Mutations and pathological-clinical findings
identified in Czech LGMD2I, 2D, 2L, 2B, and 2E probands.
Additional file 3: Table S3. In silico prediction of effects of selected
missense mutations.
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